Search Results
Aug 28, 2025, 17:46 ET Global Pharmaceutical Contract Manufacturing Market to Surpass the USD 360 Billion Mark by 2032 | DelveInsight
companies are significantly bolstering their R&D pipelines, particularly in areas such as biologics, biosimilars, and advanced modalities, including gene and cell therapies. LAS VEGAS,
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 12:03 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 28, 2025, 11:58 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 28, 2025, 10:45 ET Life Science Tools Market to Grow at a CAGR of 10.81% from 2025 to 2032 | SkyQuest Technology Consulting
microscopy, next generation sequencing, PCR & qPCR, nucleic acid preparation, nucleic acid microarray, sanger sequencing, transfection devices & gene delivery technologies, NMR, other separation technologies, other products & services. Based on technology, the market is segmented into genomic
More news about: SkyQuest Technology
Aug 28, 2025, 10:44 ET FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
local recurrence or metastasis is not only practice-changing for physicians who treat SCC, but also life-changing for their patients." The 40-gene expression profile test uses a patient's tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis and stratify patients
More news about: USA News Group
Aug 28, 2025, 10:31 ET Cancer Diagnostics Market to Grow at a CAGR of 9.4% from 2025 to 2032 | SkyQuest Technology Consulting
crucial role in helping cement the dominance of the United States going forward. Rising use of personalized medicine and gene therapies for the treatment of cancer is also expected to create new business scope for cancer diagnostics companies. High awareness among patients
More news about: SkyQuest Technology
Aug 28, 2025, 10:00 ET Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases. About AGC AGC
More news about: Celaid Therapeutics Inc.
Aug 28, 2025, 09:28 ET Made Scientific Launches Scientific Advisory Board with Appointments of Distinguished Cell Therapy Innovators Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong, M.D.
FORTE Miguel Forte, M.D., Ph.D., is CEO of Kiji Therapeutics and President of the International Society for Cell & Gene Therapy (ISCT). Prior to joining Kiji Therapeutics, he was CEO of Bone Therapeutics and Zelluna Immunotherapy, and CMO/COO of TxCell. Dr. Forte also
More news about: Made Scientific, Inc.
Aug 28, 2025, 08:35 ET The Perch at Peacock Inn to Host "Great Growths of Burgundy & Bordeaux" Wine Pairing Dinner and Rare Vintage Silent Auction
an exceptional, thoughtful collection that inspires discovery," said John Pelehaty, Hospitality Beverage Manager for Gene Hospitality. "We strive to ensure that every glass tells a story and every sip becomes a lasting memory for our guests." Event Details:
More news about: Genesis Hospitality
Aug 28, 2025, 08:30 ET Genedata Advances R&D Efficiency with New Unified Sample Management Solution
broad range of therapeutic modalities out of the box, including novel modalities such as multi-specifics, Antibody Drug Conjugates (ADCs), Cell and Gene Therapies, and RNA-LNPs. Biotherapeutics R&D involves managing a high volume of samples such as plasmids, cell banks, and purified proteins
More news about: Genedata
Aug 28, 2025, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Aug 28, 2025, 05:06 ET Trattamento clinico di base editing ad alta precisione per l'anemia falciforme: CS-101 di CorrectSequence Therapeutics ottiene risultati promettenti sul primo paziente
popolazione mondiale portatore di una variante patogena. Ogni anno ne sono colpiti circa 400.000 neonati. L'anemia falciforme, causata da mutazioni nel gene della β-globina, provoca la formazione di globuli rossi anomali, a forma di falce, con conseguenti anemia cronica, crisi dolorose ricorrenti, aumento
More news about: CorrectSequence Therapeutics
Aug 28, 2025, 04:49 ET Hochpräzise Basen-Editierung zur klinischen Behandlung der Sichelzellenkrankheit - CS-101 von CorrectSequence Therapeutics erzielt vielversprechende Ergebnisse bei erstem Patienten
Mitbegründern von Correctseq entwickelt wurde. Die Therapie zielt auf β-Hämoglobinopathien ab, indem sie ein regulatorisches Element im Promotor der γ-Globin-Gene (HBG1/2) präzise modifiziert und dabei natürlich vorkommende Einzelnukleotidvarianten nachahmt, die bei Personen mit hereditärer Persistenz von
More news about: CorrectSequence Therapeutics
Aug 27, 2025, 17:46 ET Androgen Receptor Targeted Therapies Market Forecast: Key Trends and Growth Projections Across the 7MM During the Forecast Period (2025-2034) | DelveInsight
(AR). In preclinical studies, it has shown effectiveness not only in models with normal AR expression but also in tumors that carry AR mutations or gene amplification — both of which are common resistance mechanisms to currently approved AR-targeted therapies. In April 2024,
More news about: DelveInsight Business Research, LLP
Aug 27, 2025, 15:00 ET RNAConnect® Announces Commercial Launch of UltraMarathonRT® cDNA Synthesis and Amplification Kit for Enhanced Short-Read RNA Sequencing
RNAs, enabling the capture of transcripts and retained introns that often go undetected using retroviral RT kits. Superior gene quantification, particularly for long transcripts: The ultra-processive and high-fidelity reverse transcriptase in UltraMarathonRT ensures full-length
More news about: RNAConnect
Aug 27, 2025, 14:00 ET United Methodist Communities Foundation Sponsors Free Concert Series at PNC Bank Arts Center
Presents: The Rascals 60th Anniversary Fan Appreciation Show featuring Felix Cavaliere and Gene Cornish, joined by Gary Lewis & The PlayboysClick
More news about: UMC Foundation
Aug 27, 2025, 09:34 ET duBreton Urges Animal Welfare Certifiers to Draw the Line on Gene-Edited Pork
Food & Drug Administration recently approved the use of gene-edited pork without mandatory labeling requirements or voluntary labeling guidelines. Unless brands choose to disclose it, consumers are left in the dark. Despite claims that gene-editing poses no risk to human health or animal welfare, no
More news about: duBreton
Aug 27, 2025, 09:15 ET Donors Join Forces to Support Center for Microbial Medicine at Children's Hospital of Philadelphia
Jill and Mark Fishman Center for Lymphatic Disorders. They also contributed to endeavors in prenatal gene editing aimed at curing devastating disorders and new technologies to improve recovery from life-threatening injuries. "Along with myself, the
More news about: Children's Hospital of Philadelphia
Aug 27, 2025, 08:10 ET Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
both of which are elevated in patients with EGFRi-associated skin rash. The strain was then engineered to be safe by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR04-484. About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical
More news about: Azitra, Inc.
Aug 27, 2025, 07:45 ET AccuWeather Launches Improved App with Over 50 New and Enhanced Features
Source: Kantar Research 2025 Media ContactGene PetrielloVP Corporate [email protected]
More news about: AccuWeather, Inc.
Aug 27, 2025, 07:00 ET Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Aug 27, 2025, 07:00 ET Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including
More news about: ExCellThera
Aug 27, 2025, 06:30 ET Global CAR-T Cell Therapy Market to Hit $217.6Bn by 2035 at 39.75% CAGR | Vantage Market Research
challenges.Global funding is also rising: for example, in 2024 alone, over USD 4.5 billion in venture capital funding flowed into cell and gene therapy companies.List Of Prominent Players in the CAR T-Cell Therapy Market: Celgene Corporation (U.S.)Cartesian
More news about: Vantage Market Research
Aug 26, 2025, 14:35 ET CAR-T Cell Therapy Market to Reach USD 11,142.53 million by 2032, growing at a CAGR of 12.3%: Credence Research
China)CARsgen Therapeutics Holdings Limited (China)Cartesian Therapeutics, Inc. (US)Guangzhou Bio-gene Technology Co., Ltd (China)Celgene Corporation (US)Recent Industry Developments
More news about: Credence Research Inc.
Aug 26, 2025, 13:46 ET BillionToOne's Northstar Select® Demonstrates Superior Sensitivity in Prospective Head-to-Head Validation Study Publication
actionability, covering 84 actionable and guideline-aligned genes with comprehensive coverage across SNV/indels, CNVs (including amplifications and losses), gene fusions, and microsatellite instability high detection (MSI-H). The assay achieved a five-fold better 95% limit of detection (LOD95) for CNVs2
More news about: BillionToOne